Brussels, 30/10/2013 (Agence Europe) - Experts from the pharmaceutical sector, members of the Committee for Medicinal Products for Human Use of the European Medicines Agency (CHMP) and of the Pharmacovigilance Risk Assessment Committee (PRAC) met in Vilnius on 29 and 30 October. The aim was to discuss the preparation of European strategic benchmarks for the development of European medicines and the criteria for the selection of experts for European arbitration procedures and their participation in these procedures.
The participants discussed how the medicines agencies of small European countries could compete for projects against agencies with extensive experience, and Lithuania presented its experience in such matters. The experience of the first successful cooperation between agencies in the creation of general expert teams was also presented. The experts discussed scientific news on the creation of new antibiotics and medicines against obesity, as well as problems related to the development of these drugs and solutions found to them. Experts from the PRAC discussed problems related to the implementation of the Pharmacovigilance Directive in Europe and in the member states and the steps taken to resolve these. The group of experts also discussed cooperation between services for the implementation of the pharmacovigilance regulation. (IL/transl.fl)